DENTSPLY SIRONA Balance Sheet Health
Financial Health criteria checks 3/6
DENTSPLY SIRONA has a total shareholder equity of $2.5B and total debt of $2.2B, which brings its debt-to-equity ratio to 89.7%. Its total assets and total liabilities are $6.6B and $4.1B respectively. DENTSPLY SIRONA's EBIT is $257.0M making its interest coverage ratio 3.5. It has cash and short-term investments of $296.0M.
Key information
89.7%
Debt to equity ratio
US$2.23b
Debt
| Interest coverage ratio | 3.5x |
| Cash | US$296.00m |
| Equity | US$2.49b |
| Total liabilities | US$4.14b |
| Total assets | US$6.63b |
Recent financial health updates
DENTSPLY SIRONA (NASDAQ:XRAY) Has A Somewhat Strained Balance Sheet
Jan 08
We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
May 24Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden
Feb 16These 4 Measures Indicate That DENTSPLY SIRONA (NASDAQ:XRAY) Is Using Debt Extensively
Nov 06DENTSPLY SIRONA (NASDAQ:XRAY) Has A Pretty Healthy Balance Sheet
Jul 31Is DENTSPLY SIRONA (NASDAQ:XRAY) Using Too Much Debt?
Mar 07Recent updates
DENTSPLY SIRONA (NASDAQ:XRAY) Has A Somewhat Strained Balance Sheet
Jan 08Is Now An Opportune Moment To Examine DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Dec 21DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 40% Below Their Intrinsic Value Estimate
Dec 03Dentsply Sirona: No Change To Operating Mechanics Despite Extensive Review
Nov 27DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Nov 11DENTSPLY SIRONA (NASDAQ:XRAY) Hasn't Managed To Accelerate Its Returns
Oct 13DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25Is It Time To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Sep 05Is There An Opportunity With DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) 21% Undervaluation?
Aug 18Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Have Hit The Brakes
Jul 11A Tough Macro Environment Makes Dentsply Sirona's Turnaround Even Harder
Jul 02Insufficient Growth At DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Hampers Share Price
Jun 11We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
May 24Dentsply Sirona: I'm Buying The Pullback In This Medtech Leader
Apr 24Are Investors Undervaluing DENTSPLY SIRONA Inc. (NASDAQ:XRAY) By 47%?
Apr 22There's No Escaping DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Muted Revenues
Mar 10Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden
Feb 16DENTSPLY SIRONA (NASDAQ:XRAY) Has More To Do To Multiply In Value Going Forward
Jan 29DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 28% Below Their Intrinsic Value Estimate
Jan 11Is It Too Late To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Nov 25These 4 Measures Indicate That DENTSPLY SIRONA (NASDAQ:XRAY) Is Using Debt Extensively
Nov 06Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Paint A Concerning Picture
Oct 15An Intrinsic Calculation For DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Suggests It's 46% Undervalued
Sep 18DENTSPLY SIRONA (NASDAQ:XRAY) Has A Pretty Healthy Balance Sheet
Jul 31The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing
Jul 09A Look At The Fair Value Of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)
Jun 20When Should You Buy DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Jun 02Investors Don't See Light At End Of DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Tunnel
May 15The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing
Apr 05Is DENTSPLY SIRONA (NASDAQ:XRAY) Using Too Much Debt?
Mar 07We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
Nov 09Dentsply Sirona names Glenn Coleman as new CFO
Sep 22Financial Position Analysis
Short Term Liabilities: XRAY's short term assets ($1.9B) exceed its short term liabilities ($1.5B).
Long Term Liabilities: XRAY's short term assets ($1.9B) do not cover its long term liabilities ($2.6B).
Debt to Equity History and Analysis
Debt Level: XRAY's net debt to equity ratio (77.8%) is considered high.
Reducing Debt: XRAY's debt to equity ratio has increased from 28% to 89.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable XRAY has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: XRAY is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 5.2% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 19:14 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DENTSPLY SIRONA Inc. is covered by 38 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Baird |
| Jeffrey Johnson | Baird |
| Ishan Majumdar | Baptista Research |